Matteo Giovanni Carrabba Selected Research

Cytokine Release Syndrome

11/2021

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matteo Giovanni Carrabba Research Topics

Disease

5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 11/2021
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 01/2022
1	Monosomy 01/2023
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Leukemia 01/2022
1	Residual Neoplasm 01/2022
1	Cytokine Release Syndrome 11/2021

Drug/Important Bio-Agent (IBA)

1	NucleophosminIBA 01/2023
1	ponatinibIBA 01/2022
1	venetoclaxIBA 01/2022
1	Azacitidine (5 Azacytidine)FDA Link 01/2022
1	insulin receptor-related receptor (IRR)IBA 11/2021
1	tocilizumab (atlizumab)FDA Link 11/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2021

Therapy/Procedure

2	Immunotherapy 01/2022 - 11/2021
2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2022
1	Drug Therapy (Chemotherapy) 01/2023
1	Salvage Therapy 01/2022
1	Cell Transplantation 01/2022
1	Drug Tapering 11/2021
1	Therapeutics 11/2021